Please ensure Javascript is enabled for purposes of website accessibility

Is Becton Dickinson’s Investor Lawsuit Creating A Great Buying Opportunity?

By Alex Carchidi - May 15, 2020 at 6:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite legal troubles with investors, Becton Dickinson has shown remarkable agility for its size with its COVID-19 testing program.

A group of Becton Dickinson (BDX 0.33%) shareholders are suing the healthcare company, claiming it didn't sufficiently disclose certain malfunctions of its Alaris infusion pumps product, thereby exposing the pumps to regulatory issues and delays. In early March, the Food and Drug Administration issued a recall for the Alaris pumps, stating that software issues caused 55 injuries and one death. A law firm representing BD shareholders announced its class action lawsuit shortly thereafter on March 9.

Let's look into what it means for the hospital supplies company and whether there's an attractive buying opportunity for a stock involved in potentially lucrative coronavirus work.

A stethoscope and money.

Image source: Getty Images

A series of unfortunate events

Software issues with the Alaris pump were only its latest problems to be exposed, much to the chagrin of BD's investors. Last year, the FDA issued a separate recall for the infusion tubing necessary to operate the pumps after patient injuries were reported. 

Between two separate recalls linked to catastrophic patient outcomes with the same product, it's understandable why BD shareholders would be seeking compensation. Bad press is a surefire way to pummel a company's stock price, and product recalls are expensive. Obviously, at least some of BD's shareholders are growing resentful of taking losses that they might have avoided with the information they claim BD had at the time. 

But BD is as formidable of a company as they come in the healthcare sector. BD's stock was barely affected by news of the lawsuit, and by mid-April, its losses from March were erased. 

Two equities stock chart

Image Source: YCharts

There's reason to believe that more growth is in BD's future. Despite modest second-quarter revenue growth of 1.4%, BD's manufacturing capabilities are more needed than ever in the face of the pandemic, and the company produces a massive array of products necessary for biomedical research as well as clinical operations.

A giant moves quickly to anticipate the needs of pandemic response

The largest growth opportunity for BD in the immediate future is in COVID-19 testing. BD plans to scale up its production of its rapid COVID-19 diagnostic tests as well as its production of rapid COVID-19 serology tests to detect antibodies conferring immunity. The manufacturing scale-up is intended to address a potential second wave of infections this fall. Facing rapidly expanding demand, BD could probably stick with selling its existing COVID-19 tests and make a tidy profit.

Instead, BD is developing newer and even more rapid diagnostic tests for coronavirus in response to seedlings of demand in workplaces, government, and the healthcare system. While it remains to be seen whether BD can live up to its promise of an accurate and mass-produced 15-minute diagnostic test, the attempt shows that BD is still a dynamic company when it comes to competing in rapidly emerging markets.

There's a good chance that BD will succeed in serving a lion's share of the demand for coronavirus testing as a result of its manufacturing base alone. Separately, both of BD's existing coronavirus tests on the market were rapidly expedited through the FDA emergency use authorization process without a hitch. 

Look for a dip, but don't wait too long

As the pandemic continues, BD is already positioned to profit whether or not some of its shareholders are unhappy. Though BD's deft coronavirus testing activity doesn't detract from the severity of its infusion pump fiascos, it does support the idea that there aren't any serious quality or culture issues with the company that could impair future growth. This means that prospective investors will need to plan their next moves carefully if they want to grab BD at a bargain.

Don't expect big headlines from BD, because rocking the boat isn't its game. Under normal circumstances, BD is a silent giant, avoiding intense media coverage surrounding clinical trials or new product releases like many of its healthcare sector cohorts. 

Instead, look for the unfolding of the shareholder lawsuit to briefly dent this healthcare stock's price to provide an opening for a purchase. Investors won't need to hold onto BD very long to see appreciable gains, but the longer they hold, the larger delta they'll see. It's important to keep in mind that the window of opportunity with BD is larger than it may appear. Perfectly timing a buy-in won't be necessary to benefit from the company's growth over the coming decade.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$259.40 (0.33%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.